← board
AXIM
distress 8/10 · high distress / dilution risk$0.000%today-87% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+815%
Price & events
-78.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-25.0%
1W
-25.0%
1M
-50.0%
3M
-78.6%
6M
-57.1%
1Y
-80.0%
2Y
-99.7%
5Y
-99.3%
All
Overview
- Market Cap
- $905.88K
- Enterprise Value
- $6.87M
- Volume
- 11.70K
- 52 Week Range
- $0.00 – $0.02
- Total Shares
- 301.96M
- Float Shares
- 243.75M
- % Held by Insiders
- 22.39%
- % Held by Institutions
- 0.00%
- RVOL
- 0.07x
- Beta
- -0.15
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 301,958,824 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.